Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Neuropsychopharmacology 40 , 10841090 (2015)
Merck has built a patent estate around pembrolizumab that includes composition-of-matter patents on the antibody structure, method-of-use patents covering its approved indications (pembrolizumab has over 40 FDA-approved indications and indication-specific dosing regimens), and formulation patents on its IV formulation and concentration
It is important not to exceed the doses indicated by health professionals or on supplement labelling to avoid adverse side effects
The information is deemed to be defined as Technical Analysis and is not defined as a Research Report under Rule 2241
US$ 28.90
US$ 27.14
US$ 26.42
US$ 26.04
